Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.

The Main Stage on the show floor will host daily programming featuring thought leadership sessions, expert panels and the ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

The MedTech segment provides solutions for heart disorders, stroke, orthopedics, surgeries, and vision care. Johnson & Johnson (NYSE:JNJ) ranks 4th on our list of the best dividend stocks.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus forecast.